Myasthenia Gravis (MG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Myasthenia Gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigue. It is a B-cell mediated condition, with antibodies targeting the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or the postsynaptic membrane at the neuromuscular junction. Auto-antibodies against the acetylcholine receptor (AChR), muscle-specific kinase, and lipoprotein-related protein four are well-established diagnostic markers and pathogenic factors. These auto-antibodies play a crucial role in classifying Myasthenia Gravis patients into subgroups. Fortunately, modern treatments offer a positive prognosis for MG patients, including immunosuppression, symptom management, and support. Most individuals with mild to moderate symptoms achieve complete remission or significant improvement. MG can be categorized into five types: congenital myasthenia gravis, generalized myasthenia gravis, ocular myasthenia gravis, transient neonatal myasthenia gravis, and juvenile myasthenia gravis, based on disease onset timing, neuromuscular dysfunction cause, and affected muscle groups.

·       The incidence of the Myasthenia Gravis is estimated to be 4.1 to 30 cases per million person-years.

 

Thelansis’s “Myasthenia Gravis (MG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myasthenia Gravis (MG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Myasthenia Gravis (MG) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Myasthenia Gravis (MG) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Myasthenia Gravis (MG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Myasthenia Gravis (MG), Myasthenia Gravis (MG) market outlook, Myasthenia Gravis (MG) competitive landscape, Myasthenia Gravis (MG) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)